Top 5 Biotech Stocks For 2019


Barclays upgraded shares of Sarepta Therapeutics (NASDAQ:SRPT) from an equal weight rating to an overweight rating in a research report released on Friday morning, MarketBeat.com reports. They currently have $107.00 target price on the biotechnology company’s stock, up from their prior target price of $55.00.

Several other brokerages have also recently weighed in on SRPT. UBS cut Sarepta Therapeutics from an outperform rating to a market perform rating in a report on Friday, May 4th. BidaskClub raised Sarepta Therapeutics from a buy rating to a strong-buy rating in a report on Friday, April 13th. Oppenheimer cut Sarepta Therapeutics from an outperform rating to a market perform rating in a report on Friday, May 4th. HC Wainwright set a $96.00 price target on Sarepta Therapeutics and gave the company a buy rating in a research note on Friday, May 4th. Finally, JPMorgan Chase reaffirmed an overweight rating and issued a $75.00 price target (up from $63.00) on shares of Sarepta Therapeutics in a research note on Wednesday, February 21st. Five equities research analysts have rated the stock with a hold rating, seventeen have issued a buy rating and two have given a strong buy rating to the company’s stock. Sarepta Therapeutics has a consensus rating of Buy and a consensus price target of $85.50.

Top 5 Biotech Stocks For 2019: Biogen Idec Inc(BIIB)


Advisors’ Opinion:

  • [By Chris Lange]

    Short interest in Biogen Inc. (NASDAQ: BIIB) decreased to 3.45 million shares from the previous 3.50 million. The stock recently traded at $274.50, within a 52-week range of $244.28 to $370.57.

  • [By Joseph Griffin]

    Here are some of the news stories that may have effected Accern’s analysis:

    Get Biogen alerts:

    Biogen (BIIB) Expected to Post Quarterly Sales of $3.24 Billion (americanbankingnews.com) Biogen Inc (NASDAQ:BIIB): Does The Earnings Decline Make It An Underperformer? (finance.yahoo.com) 5 Trade Ideas For Monday: AMTD, BIIB, DEO, FITB, TECK (investing.com) $5.29 EPS Expected for Biogen (BIIB) This Quarter (americanbankingnews.com) Biogen (BIIB) Upgraded by ValuEngine to “Hold” (americanbankingnews.com)


    Shares of Biogen traded up $5.45, reaching $281.51, during midday trading on Wednesday, according to MarketBeat Ratings. 1,514,169 shares of the company’s stock were exchanged, compared to its average volume of 1,729,786. Biogen has a 52-week low of $276.94 and a 52-week high of $281.57. The firm has a market cap of $59.58 billion, a price-to-earnings ratio of 12.91, a PEG ratio of 1.65 and a beta of 0.84. The company has a debt-to-equity ratio of 0.42, a quick ratio of 2.95 and a current ratio of 3.23.

  • [By Todd Campbell]

    Unfortunately for investors, June’s discovery wasn’t exciting enough for Sangamo partners Biogen (NASDAQ:BIIB) and Shire (NASDAQ:SHPG). In 2015, Biogen announced a delay to its beta-thalassemia and sickle-cell disease treatment program with Sangamo. And then Shire, a Sangamo collaboration partner since 2012, walked away from Sangamo’s hemophilia program.

  • [By Cory Renauer]

    There’s a lot for investors to like about Amgen Inc. (NASDAQ:AMGN) and Biogen Inc. (NASDAQ:BIIB). Both of these biotech stocks have produced tremendous returns over the past couple of decades, and the businesses they represent still generate enormous profits. 

Top 5 Biotech Stocks For 2019: ArQule Inc.(ARQL)

Advisors’ Opinion:

  • [By Lisa Levin] Gainers
    Melinta Therapeutics, Inc. (NASDAQ: MLNT) shares surged 20.6 percent to $6.39. WBB Securities upgraded Melinta Therapeutics from Hold to Speculative Buy.
    Shoe Carnival, Inc. (NASDAQ: SCVL) shares climbed 17.2 percent to $30.87 after the company reported upbeat quarterly earnings.
    Acorn International, Inc. (NYSE: ATV) shares rose 15.2 percent to $28.804 after the company declared a special one-time cash dividend of $14.97 per ADS.
    Foot Locker, Inc. (NYSE: FL) gained 15 percent to $53.35 after the company reported better-than-expected results for its first quarter.
    Sears Hometown and Outlet Stores, Inc. (NASDAQ: SHOS) surged 14.2 percent to $2.625.
    ArQule, Inc. (NASDAQ: ARQL) rose 13 percent to $5.12 after gaining 4.86 percent on Thursday.
    Quality Systems, Inc. (NASDAQ: QSII) gained 12.8 percent to $16.97 after the company posted better-than-expected FQ4 results.
    Loma Negra Compañía Industrial Argentina Sociedad Anónima (NYSE: LOMA) shares rose 12 percent to $12.94.
    ArQule, Inc. (NASDAQ: ARQL) shares rose 12 percent to $5.07.
    Mirati Therapeutics, Inc. (NASDAQ: MRTX) climbed 11.4 percent to $43.50.
    Zai Lab Limited (NASDAQ: ZLAB) gained 11.3 percent to $24.7000.
    Zymeworks Inc. (NASDAQ: ZYME) rose 9.7 percent to $19.64.
    Park City Group, Inc. (NASDAQ: PCYG) climbed 9 percent to $7.90.
    Roku, Inc. (NASDAQ: ROKU) gained 7.9 percent to $38.82 after Citron reversed previously bearish position on the stock.
    Sears Holdings Corporation (NASDAQ: SHLD) shares jumped 7.3 percent to $3.55.
    Deckers Outdoor Corp (NYSE: DECK) rose 3.5 percent to $107.27 after reporting better-than-expected results for its fiscal fourth quarter.


    Check out these big penny stock gainers and losers

  • [By Joseph Griffin]

    ArQule (NASDAQ:ARQL)‘s stock had its “buy” rating restated by equities researchers at Needham & Company LLC in a research report issued to clients and investors on Tuesday, Marketbeat Ratings reports. They currently have a $6.00 price target on the biotechnology company’s stock, up from their prior price target of $5.00. Needham & Company LLC’s price target suggests a potential upside of 134.38% from the company’s previous close.

  • [By Joseph Griffin]

    ValuEngine upgraded shares of ArQule (NASDAQ:ARQL) from a buy rating to a strong-buy rating in a research report released on Tuesday.

    Several other equities analysts have also issued reports on ARQL. Zacks Investment Research upgraded ArQule from a hold rating to a buy rating and set a $2.50 price objective for the company in a research report on Tuesday, March 20th. BidaskClub upgraded ArQule from a buy rating to a strong-buy rating in a research report on Saturday, March 24th. B. Riley set a $4.00 price objective on ArQule and gave the company a buy rating in a research report on Monday, March 26th. Leerink Swann upgraded ArQule from a market perform rating to an outperform rating in a research report on Thursday, April 5th. Finally, Roth Capital boosted their price objective on ArQule from $5.00 to $6.00 and gave the company a buy rating in a research report on Tuesday, April 17th. One equities research analyst has rated the stock with a sell rating, five have assigned a buy rating and two have issued a strong buy rating to the stock. The company has a consensus rating of Buy and a consensus target price of $5.35.

  • [By Logan Wallace]

    ValuEngine downgraded shares of ArQule (NASDAQ:ARQL) from a strong-buy rating to a buy rating in a research report sent to investors on Saturday.

    Several other brokerages also recently issued reports on ARQL. Zacks Investment Research upgraded shares of ArQule from a hold rating to a buy rating and set a $2.75 target price for the company in a research note on Tuesday, May 8th. B. Riley set a $4.00 target price on shares of ArQule and gave the company a buy rating in a research note on Monday, March 26th. Roth Capital raised their target price on shares of ArQule from $5.00 to $6.00 and gave the company a buy rating in a research note on Tuesday, April 17th. BidaskClub upgraded shares of ArQule from a hold rating to a buy rating in a research note on Saturday, May 19th. Finally, Leerink Swann upgraded shares of ArQule from a market perform rating to an outperform rating in a research note on Thursday, April 5th. One research analyst has rated the stock with a sell rating, six have issued a buy rating and one has issued a strong buy rating to the company. The company has an average rating of Buy and a consensus price target of $5.35.

  • [By Stephan Byrd]

    ArQule, Inc. (NASDAQ:ARQL)’s share price rose 6.2% during trading on Thursday . The stock traded as high as $5.21 and last traded at $5.15. Approximately 955,706 shares changed hands during mid-day trading, a decline of 23% from the average daily volume of 1,244,948 shares. The stock had previously closed at $4.85.

  • [By Cory Renauer]

    What’s behind these dramatic gains? Read on to find out.

    Company Gain in H1 2018 Market Cap
    Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) 270% $1.19 billion
    ArQule, Inc. (NASDAQ:ARQL) 235% $482 million
    Endocyte, Inc. (NASDAQ:ECYT) 222% $959 million
    Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) 205% $3.99 billion


    Data source: YCharts.

Top 5 Biotech Stocks For 2019: Alnylam Pharmaceuticals Inc.(ALNY)

Advisors’ Opinion:

  • [By Motley Fool Staff]

    Alnylam’s (NASDAQ:ALNY) Onpattro is the first Food and Drug Administration (FDA)-approved RNAi therapy. However, competition is fast approaching and could make it difficult for Alnylam to pocket profits. Can Onpattro carve out significant sales as a treatment for polyneuropathy in hereditary transthyretin-mediated (hATTR) amyloidosis?

  • [By Logan Wallace]

    Alnylam Pharmaceuticals (NASDAQ:ALNY) was downgraded by analysts at Zacks Investment Research from a hold rating to a sell rating. According to Zacks, “Although Alnylam has a broad and promising pipeline, we note that most candidates are in mid stages of development. These candidates still have a long way to go before hitting the market. The company relies highly on collaborators for funding. Any development/regulatory setback would be a negative for the company.  However, Alnylam reported positive data from the ATLAS study in the first quarter which led to regulatory filings for its late-stage pipeline candidate patisiran and the FDA set an action date of Aug 11, 2018. The company along with its partners Sanofi and The Medicines Company, restarted fitusiran's ATLAS phase III study and advanced inclisiran in the ORION-9, -10, and -11 phase III studies, respectively, with results expected for both programs in 2019. Alnylam expects to achieve the profile of three marketed products by the end of 2020.”

  • [By Shane Hupp]

    Get a free copy of the Zacks research report on Alnylam Pharmaceuticals (ALNY)

    For more information about research offerings from Zacks Investment Research, visit Zacks.com

  • [By Brian Orelli]

    The delay in an FDA decision for Tegsedi puts it behind competitor Alnylam Pharmaceuticals (NASDAQ:ALNY), which expects to hear from the FDA by Aug. 11 for its hATTR drug patisiran. But Sarah Boyce, the president at Akcea Therapeutics, doesn’t think a few months will really matter: “We don’t really feel that’s going to have any impact and the drugs will be close enough together from a launch perspective. So not really [going] to make any adjustments, and we’re very well prepared to be ready to launch following approval.”

Top 5 Biotech Stocks For 2019: Amgen Inc.(AMGN)

Advisors’ Opinion:

  • [By Stephan Byrd]

    Get a free copy of the Zacks research report on Amgen (AMGN)

    For more information about research offerings from Zacks Investment Research, visit Zacks.com

  • [By Joseph Griffin]

    South Dakota Investment Council lowered its stake in Amgen (NASDAQ:AMGN) by 59.4% during the 1st quarter, HoldingsChannel reports. The fund owned 77,041 shares of the medical research company’s stock after selling 112,589 shares during the quarter. South Dakota Investment Council’s holdings in Amgen were worth $13,134,000 at the end of the most recent quarter.

  • [By Max Byerly]

    Amgen (NASDAQ: AMGN) and aTyr Pharma (NASDAQ:LIFE) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their profitability, valuation, dividends, earnings, risk, analyst recommendations and institutional ownership.